Clinical Trial

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Study acronym: EndoMAP
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2020-07-23; most recent amendment 2026-03-31.
Status change: Not Yet Recruiting → Recruiting 2021-09-23
Trial Details
NCT Number NCT04486352
Lead Sponsor Alliance Foundation Trials, LLC.
Collaborators: Genentech, Inc., Foundation Medicine, Pfizer, Eli Lilly and Company
Conditions Endometrial Cancer
Enrollment 148 participants
Start Date 2021-10-20
Primary Completion 2026-10-01 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-01